First patient dosed in Phase II OCULE-01 study with roginolisib, an allosteric modulator of PI3Kd The European Medicines Agency (EMA) has granted Orphan Drug Designation for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback